Pharmacokinetic characteristics and tissue residues for marbofloxacin and its metabolite N-desmethyl-marbofloxacin in broiler chickens

American Journal of Veterinary Research

Volumn 63, Issue 7, 2002, Pages 927-933

  Anadón, Arturo ^a   Martínez Larrañaga, María R ^a   Díaz, María J ^a   Martínez, María A ^a   Frejo, María T ^a   artínez, Marta ^a   Tafur, McAllister ^a   Castellano, Victor J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; DRUG RESIDUE; MARBOFLOXACIN; N DESMETHYL MARBOFLOXACIN; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANIMAL TISSUE; ARTICLE; CHICKEN; CONTROLLED STUDY; DATA ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFECTION CONTROL; KIDNEY PARENCHYMA; MALE; MEAN RESIDENCE TIME; MUSCLE TISSUE; NONHUMAN; SKIN; ANIMAL; ANIMAL DISEASE; AREA UNDER THE CURVE; BIOAVAILABILITY; BLOOD; CHEMISTRY; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER; METABOLISM; MUSCLE; ORAL DRUG ADMINISTRATION; RANDOMIZATION;

ANIMALIA; GALLUS GALLUS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHICKENS; DRUG RESIDUES; FLUOROQUINOLONES; HALF-LIFE; INJECTIONS, INTRAVENOUS; KIDNEY; LIVER; MALE; MUSCLES; QUINOLONES; RANDOM ALLOCATION; SKIN;

EID: 0035985432     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2002.63.927     Document Type: Article

References (47)

1. Fluoroquinolones in animal health
2. The use of fluoroquinolones for companion animal antimicrobial therapy
3. DNA gyrase and the supercoiling of DNA
4. DNA topoisomerases
5. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: Specificity and cooperativity of drug binding to DNA
6. The fluoroquinolone antimicrobials: Structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity
7. Les fluoroquinolones: Aspects pharmacologiques et toxicologiques
8. Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates
9. Update on the sensitivity of recent European canine and feline pathogens to marbofloxacin
10. Utilisation de la marbofloxacin dans le traitement des pyodermites du chien
11. The use of fluoroquinolones in veterinary dermatology
12. Therapy of difficult cases of canine pyoderma with marbofloxacin: A report of 39 dogs
13. Antibacterial susceptibility patterns of Pseudomonas strains isolated from chronic canine otitis externa
14. Comparative study of marbofloxacin and amoxicillin-clavulanic acid in the treatment of urinary tract infections in dogs
15. Comparative field evaluation of marbofloxacin tablets in the treatment of feline upper respiratory infections
16. Efficacité et innocuité comparées de la marbofloxacine et de l'oxytétracycline dans le traitement des maladies respiratoires des jeunes bovins
17. Field evaluation of efficacy and tolerance of a 2% marbofloxacin injectable solution for the treatment of respiratory disease in fattening pigs
18. Prevention of surgical infections in dogs with a single intravenous injection of marbofloxacin: An experimental model
19. Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration
20. Pharmacokinetics of the gyrase inhibitor marbofloxacin: Influence of pregnancy and lactation in sows
21. Pharmacokinetics and penetration of marbofloxacin from blood into the milk of cows and ewes
22. Effect of experimental renal impairment on disposition of marbofloxacin and its metabolites in the dog
23. The disposition of marbofloxacin in Eurasian buzzards (Buteo buteo) after intravenous administration
24. A program for the extended least squares fit to individual pharmacokinetic data A technical report of the division of clinical pharmacology
25. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations
26. Estimating the dimension of a model
27. Chapter 2, More complicated models
28. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data
29. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time
30. Pharmacokinetics of norfloxacin and its N-desethyl- and oxometabolites in broiler chickens
31. Pharmacokinetics and residues of enrofloxacin in chickens
32. Clinical pharmacokinetics of the newer antibacterial 4-quinolones
33. In vitro susceptibility of avian Escherichia coli and Pasteurella multocida to danofloxacin and five other antimicrobials
34. Pharmacodynamics of the fluoroquinolones
35. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection
36. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens
37. Quinolone resistance in clinical practice: Occurrence and importance
38. Mechanisms of resistance to quinolones
39. Mechanisms of resistance to fluoroquinolones: State-of-the-art 1992-1994
40. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa
41. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
42. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections
43. Correlation of pharmacokinetic parameters to efficacy of antibiotics: Relationship between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia
44. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
45. Antimicrobial medication in domestic poultry